←
Loading live data…
PRICE
Loading…
REVENUE MIX
Total Revenue100%
COST
COGS57%
R&D + SG&A30%
Op Margin13%
FINANCIAL HEALTH
REVENUE
$46.4B
Growth
-1%
Gross M.
43%
P/E
19.5
EV/EBITDA
12.8
Net M.
7%
FCF M.
4%
D/E
0.53
Op M.
13%
PLUG INTO YOUR DCF
Historical growth
0.8%
Analyst 5y growth
—
Forward P/E
17.9
PEG ratio
1.50
Trailing EPS
$2.10
Forward EPS
$2.30
🚩 RED FLAG SCANNER — 10-K RISK FACTORS, YEAR OVER YEAR
TAM
SIZE
—
CAGR
—
Market-size estimates aren't available for this stock right now — see Financial Health and Risk Assessment below for a fundamentals-based read instead.
RISK ASSESSMENT
MEDTrading above a mechanical base-case DCF estimate of $38.42 (default assumptions) — priced for continued strong execution.
LOWDebt/equity of 0.53 — conservative balance sheet.
HIGRevenue declining 1% YoY — shrinking top line pressures margins and the multiple.
🐂 BULL
NKE shows 13% operating margin, 22% ROE — a business converting growth into real profit.
🐻 BEAR
At a P/E of 19.5 and EV/EBITDA of 12.8, the stock is priced for continued execution — any deceleration in growth or margin compression would likely pressure the multiple.
AI-powered data, computed by TreasureX · May contain inaccuracies
⚠️
All values, scores, and figures here are computed from your own assumptions and public data, for educational purposes only. This is not investment advice — TreasureX does not recommend buying or selling any security. Results change with your inputs. Please do your own research and use your own judgement before making any investment decision.